Skip to main content
Premium Trial:

Request an Annual Quote

Lunaphore Technologies Raises Additional $2.1M in Series C Financing

NEW YORK Lunaphore Technologies on Tuesday announced it has raised CHF 2 million ($2.1 million) in Series C2 financing, bringing the total revenues for its Series C round to CHF 25 million.

Swiss Entrepreneurs Fund invested all CHF 2 million in the Series C2 financing round, bringing its total investment in Lunaphore to CHF 5 million. The Swiss Entrepreneurs fund is linked to the Swiss Entrepreneurs Foundation, whose focus is to invest in Swiss startups and small- and medium-sized enterprises in a growth phase, Lunaphore said.

In February, the Lausanne, Switzerland-based company had announced it raised CHF 23 million in its Series C round.

The proceeds from the overall Series C financing will be dedicated to market and product expansion, including a US market entry, the ramp up of activities in Europe, and the development of next-generation instruments, the firm said.

Lunaphore is developing next-generation tissue autostainers that use microfluidics to perform assays on cancer patient tissue samples.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.